MedPath

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Phase 1
Completed
Conditions
Biliary Tract Cancer
Secondary Liver Cancer
Liver Metastases
Carcinoma, Hepatocellular
Interventions
Registration Number
NCT04338685
Lead Sponsor
Hoffmann-La Roche
Brief Summary

Phase I study of RO7119929 given orally to participants with unresectable advanced or metastatic primary liver cancers and other solid tumors with predominant liver involvement. The primary objective of the study is to explore the safety and to determine the maximum tolerated dose (MTD) and/or optimal biologic dose (OBD) of RO7119929 as single agent.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
55
Inclusion Criteria
  • Histologically confirmed diagnosis of one of the following: unresectable advanced or metastatic HCC (including fibrolamellar HCC) not amenable to a curative treatment approach, unresectable advanced or metastatic intrahepatic or perihilar (Klatskin) BTC not amenable to a curative treatment approach, extrahepatic BTC or gallbladder cancer infiltrating the liver or metastasized into the liver with predominant liver disease, not amenable to a curative treatment approach, metastasized colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), Gastric cancer (GC), renal cell carcinoma (RCC), triple negative breast cancer (TNBC), cutaneous melanoma, or ocular melanoma with predominant liver disease not amenable to a curative treatment approach. Participants with other solid tumors with predominant liver disease not amenable to a curative treatment approach might be enrolled after Sponsor approval
  • Measurable disease with at least one measurable locally untreated liver lesion, as defined by RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Adequate hematologic and major organ functions
  • Participants for which there is no available standard therapy likely to confer clinical benefit, or participants who are not candidates for such available therapy
  • Life expectancy of ≥12 weeks, approximated with Royal Marsden Hospital score 0-1 or Gustave Roussy Immune (GRIm) score 0-1. Participants with a Royal Marsden Hospital or GRIm score of ≥2 and a life expectancy of ≥12 weeks according to the investigator's clinical judgement may be enrolled after Medical Monitor approval has been obtained.
  • For participants with HCC: Child-Pugh score of A6 or better
Exclusion Criteria
  • History or clinical evidence of central nervous system (CNS) primary tumors or metastases including leptomeningeal metastases, unless they have been previously treated, are asymptomatic, and have had no requirement for steroids or enzyme-inducing anticonvulsants in the last 14 days prior to Screening
  • Evidence of any extra-hepatic primary tumor or metastasis requiring prompt medical intervention
  • Receipt of prior therapy with a TLR7/8/9 agonist and/or IFN-alpha
  • Prior chemotherapy, antibody, or other registered or experimental cancer treatment within 3 weeks of study Cycle 1 Day 1. Specifically, no CPI antibody is allowed to be administered within 6 weeks of study Cycle 1 Day 1
  • Receipt of investigational agent for any other indication within 3 weeks of dosing
  • Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment
  • Local therapy to liver (e.g. radiofrequency ablation, percutaneuous ethanol or acetic acid injection, cryoablation, high-intensity focused ultrasound, transarterial chemoembolization, and transarterial embolization) within 3 weeks prior to initiation of study treatment, radioembolization within 3 months prior to initiation of study treatment, or non-recovery from side effects of such procedure
  • Treatment-related toxicities from prior cancer therapy that have not resolved to </= Grade 1 CTC AE prior to study treatment with the exception of the following Grade 2 toxicities:

alopecia, peripheral neuropathy, any laboratory changes that still lie within the inclusion criteria defined above

  • History of other malignancy within 2 years; exception for ductal carcinoma in situ not requiring chemotherapy, low grade cervical intraepithelial neoplasia (CIN), nonmelanoma skin cancer, low grade localized prostate cancer (Gleason score < Grade 7), or optimally treated Stage 1 uterine cancer.
  • Active or history of immunologic-mediated disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren's syndrome or Guillain-Barré syndrome
  • Known active or uncontrolled bacterial, viral, fungal, mycobacterial, parasitic, or other infection.
  • Ascites, pleural effusion, or pericardial effusion requiring medical intervention within 12 months prior to study entry.
  • History of human immunodeficiency virus (HIV) infection
  • Active hepatitis B virus (HBV) infection
  • Coinfection of HBV and hepatitis C virus (HCV).

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Part A1 - 6 mg RO7119929RO7119929Participants received 6 mg RO7119929 every week in 3-week cycles
Part B1-5 mg RO7119929RO7119929Participants with both available and evaluable tumor biopsy samples received 5 mg RO7119929 on Cycle 1 Day 1 to month 12
Part A3-4 mg RO7119929RO7119929Participants received tocilizumab pre-treatment on Cycle 1 Day 1, approximately 2 hours prior to RO7119929 administration and 4 mg RO7119929 every week in 3-week cycles
Part A1-3 mg RO7119929RO7119929Participants received 4 mg RO7119929 every week in 3-week cycles
Part A1-1 mg RO7119929RO7119929Participants received 1mg RO7119929 every week in 3-week cycles.
Part A1 -9 mg RO7119929RO7119929Participants received 9 mg RO7119929 every week in 3-week cycles
Part A2- 2/5/6 mg RO7119929RO7119929Participants received RO7119929 QW with step-up dosing of 2/5/6 mg during Cycle 1.
Part A2- 2/5/5 mg RO7119929RO7119929Participants received RO7119929 QW with step-up dosing of 2/5/5 mg during Cycle 1.
Part A3-4 mg RO7119929TocilizumabParticipants received tocilizumab pre-treatment on Cycle 1 Day 1, approximately 2 hours prior to RO7119929 administration and 4 mg RO7119929 every week in 3-week cycles
Primary Outcome Measures
NameTimeMethod
Number of Participants With Dose-Limiting Toxicities (DLT)Baseline up to approximately 14 months

A DLT is defined as a clinically significant AE (classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v.5.0) or significant laboratory abnormality 1) occurring during an assessment period of 21 days or 28 days after first dose of study treatment, respectively, and 2) is not attributed to disease progression, concomitant illness or another clearly identifiable cause.

Number of Participants With Adverse Events (AEs) According To NCI CTCAE v5.0Baseline up to approximately 14 months

An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Secondary Outcome Measures
NameTimeMethod
Maximum Concentration (Cmax) for RO7119929 Following Administration of RO7119929Cycle 1, after 1st dose, Cycle 2, after 4th dose (Each cycle is 21 days)
Maximum Concentration (Cmax) for RO7119929 Following Administration of RO7119929, Oral Step-Up DoseCycle 1 Day 15, Cycle 2 Day 1 (Cycle duration is 21 days)
Time of Maximum Concentration Observed (Tmax) for RO7119929 Following Administration of RO7119929Cycle 1, after 1st dose, Cycle 2, after 4th dose (Each cycle is 21 days)
Time of Maximum Concentration Observed (Tmax) for RO7119929 Following Administration of RO7119929, Oral Step-Up DoseCycle 1 Day 15, Cycle 2 Day 1 (Cycle duration is 21 days)
Area Under the Curve (AUC) for RO7119929 Following Administration of RO7119929Cycle 1, after 1st dose, Cycle 2, after 4th dose (Each cycle is 21 days)
Area Under the Curve (AUC) for RO7119929 Following Administration of RO7119929, Oral Step-Up DoseCycle 1 Day 15, Cycle 2 Day 1 (Cycle duration is 21 days)
Half-Life (T1/2) for RO7119929 Following Administration of RO7119929Cycle 1, after 1st dose, Cycle 2, after 4th dose (Each cycle is 21 days)
Half-Life (T1/2) for RO7119929 Following Administration of RO7119929, Oral Step-Up DoseCycle 1 Day 15, Cycle 2 Day 1 (Cycle duration is 21 days)
Progression-Free Survival (PFS) According to RECIST v1.1Baseline up to approximately 14 months

Progression-free survival (PFS) is defined as the time from randomization to disease progression or death from any cause.

Objective Response Rate (ORR) According to RECIST v1.1Baseline up to approximately 14 months

ORR is defined as the number of patients who achieve a response, which can either be complete response (complete disappearance of lesions) or partial response (reduction in the sum of maximal tumor diameters by at least 30% or more).

Overall Survival (OS)Baseline up to approximately 14 months

Overall survival (OS) is defined as the time from randomization to death

Trial Locations

Locations (10)

Rigshospitalet; Onkologisk Klinik

🇩🇰

København Ø, Denmark

City of Hope Cancer Center

🇺🇸

Duarte, California, United States

Queen Mary Hospital; Dept of Medicine

🇭🇰

Hong Kong, Hong Kong

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Clínica Universidad de Navarra

🇪🇸

Pamplona, Navarra, Spain

Hospital Universitari Vall d'Hebron; Oncology

🇪🇸

Barcelona, Spain

National Taiwan Uni Hospital

🇨🇳

Taipei City, Taiwan

Tri-Service General Hospital

🇨🇳

Taipei, Taiwan

Clinica Universidad de Navarra Madrid; Servicio de Oncología

🇪🇸

Madrid, Spain

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath